Business Description
Immix Biopharma Inc
NAICS : 541715
SIC : 2833
ISIN : US45258H1068
Total Employee Number:
21Description
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 87.35 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -14.9 | |||||
3-Year EPS without NRI Growth Rate | -14.7 | |||||
3-Year FCF Growth Rate | -12 | |||||
3-Year Book Growth Rate | 23.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.75 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.73 | |||||
9-Day RSI | 65.35 | |||||
14-Day RSI | 62.25 | |||||
3-1 Month Momentum % | -7.68 | |||||
6-1 Month Momentum % | 60.2 | |||||
12-1 Month Momentum % | 210.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.75 | |||||
Quick Ratio | 8.75 | |||||
Cash Ratio | 8.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -56.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -87.17 | |||||
ROA % | -68.26 | |||||
ROIC % | -846.78 | |||||
3-Year ROIIC % | -484.55 | |||||
ROC (Joel Greenblatt) % | -1094.6 | |||||
ROCE % | -87.8 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.57 | |||||
Price-to-Tangible-Book | 6.57 | |||||
EV-to-EBIT | -18.14 | |||||
EV-to-EBITDA | -18.36 | |||||
EV-to-Forward-Revenue | 7.25 | |||||
EV-to-FCF | -19.97 | |||||
| Price-to-Net-Current-Asset-Value | 6.88 | |||||
| Price-to-Net-Cash | 7.01 | |||||
Earnings Yield (Greenblatt) % | -5.51 | |||||
FCF Yield % | -4.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMMX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immix Biopharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.92 | ||
| Beta | -0.477 | ||
| 3-Year Sharpe Ratio | 0.85 | ||
| 3-Year Sortino Ratio | 1.79 | ||
| Volatility % | 89.73 | ||
| 14-Day RSI | 62.25 | ||
| 14-Day ATR ($) | 0.754435 | ||
| 20-Day SMA ($) | 9.2035 | ||
| 12-1 Month Momentum % | 210.98 | ||
| 52-Week Range ($) | 1.94 - 11.6099 | ||
| Shares Outstanding (Mil) | 71.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immix Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immix Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 31 days | ||
| General meeting for 2026 | 2026-05-22 12:00 | 8.67 (-4.73%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 10.32 (+7.95%) | ||
| Annual report for 2025 | 2026-03-25 | 8.57 (-1.38%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 | 10.13 (+10.71%) | ||
| Guidance call for 2026 | 2026-03-08 | 9.29 (+11.26%) | ||
| Guggenheim 2nd Annual Healthcare Innovation Conference | 2025-11-11 12:30 | 3.24 (-0.61%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 3.03 (-0.98%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 2.39 (-8.78%) |
Show
Entries
Immix Biopharma Inc Frequently Asked Questions
What is Immix Biopharma Inc(IMMX)'s stock price today?
The current price of IMMX is $10.45. The 52 week high of IMMX is $11.61 and 52 week low is $1.94.
When is next earnings date of Immix Biopharma Inc(IMMX)?
The next earnings date of Immix Biopharma Inc(IMMX) is 2026-08-07 Est..
Does Immix Biopharma Inc(IMMX) pay dividends? If so, how much?
Immix Biopharma Inc(IMMX) does not pay dividend.
Guru Commentaries on NAS:IMMX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Immix Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers